Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?

Brizzi, Marisa; Pérez, Sarah E.; Michienzi, Sarah M; Badowski, Melissa E

doi:10.1177/20499361221149773

Cited by 6 publications

(3 citation statements)

References 34 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-acting formulations such as implants, rings, and nanoformulations are also future hallmarks of anti-HIV-1 drug development. The co-packaged cabotegravir (extendedrelease injectable suspension) and rilpivirine (extended-release injectable suspension) (Cabenuva ® ) is the first FDA-approved injectable complete regimen for adults with HIV-1 infection [160,161].…”

Section: Pharmacokinetic Enhancersmentioning

confidence: 99%

A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

Sever,

Otsuka,

Fujita

et al. 2024

IJMS

View full text Add to dashboard Cite

Acquired immunodeficiency syndrome (AIDS) is an enormous global health threat stemming from human immunodeficiency virus (HIV-1) infection. Up to now, the tremendous advances in combination antiretroviral therapy (cART) have shifted HIV-1 infection from a fatal illness into a manageable chronic disorder. However, the presence of latent reservoirs, the multifaceted nature of HIV-1, drug resistance, severe off-target effects, poor adherence, and high cost restrict the efficacy of current cART targeting the distinct stages of the virus life cycle. Therefore, there is an unmet need for the discovery of new therapeutics that not only bypass the limitations of the current therapy but also protect the body’s health at the same time. The main goal for complete HIV-1 eradication is purging latently infected cells from patients’ bodies. A potential strategy called “lock-in and apoptosis” targets the budding phase of the life cycle of the virus and leads to susceptibility to apoptosis of HIV-1 infected cells for the elimination of HIV-1 reservoirs and, ultimately, for complete eradication. The current work intends to present the main advantages and disadvantages of United States Food and Drug Administration (FDA)-approved anti-HIV-1 drugs as well as plausible strategies for the design and development of more anti-HIV-1 compounds with better potency, favorable pharmacokinetic profiles, and improved safety issues.

show abstract

Section: Pharmacokinetic Enhancersmentioning

confidence: 99%

A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

Sever,

Otsuka,

Fujita

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Long-acting formulations such as implants, rings and nanoformulations are also future hallmarks of anti-HIV-1 drug development. The co-packaged cabotegravir (extended-release injectable suspension) and rilpivirine (extended-release injectable suspension) (Cabenuva ® ) is the first FDA-approved injectable, complete regimen for adults with HIV-1 infection [160,161].…”

Section: Standard Two-drug Three-drug and Four-drug Regimens And Fixe...mentioning

confidence: 99%

A Review on FDA Approved Anti-HIV-1 Drugs, Anti-Gag Compounds and Potential Strategies for HIV-1 Eradication

Sever,

Otsuka,

Fujita

et al. 2024

Preprint

View full text Add to dashboard Cite

Acquired immunodeficiency syndrome (AIDS) is an enormous global health threat stemming from human immunodeficiency virus (HIV-1) infection. Up to now, the tremendous advances in combination antiretroviral therapy (cART) have shifted HIV-1 infection from a fatal illness into a manageable chronic disorder. However, the presence of latent reservoirs, multifaceted nature of HIV-1, drug resistance, severe off-target effects, poor adherence, and high cost restrict the efficacy of current cART targeting the distinct stages of the virus life cycle. Therefore, there is an unmet need for discovery of new therapeutics that not only bypass the limitations of the current therapy but also protect the body health at the same time. The main goal for complete HIV-1 eradication is purging latently infected cells from the patients’ bodies. A potential strategy called “lock-in apoptosis” targeting the budding phase of life cycle of virus leading to susceptibility to apoptosis of HIV-1 infected cells for elimination of HIV-1 reservoirs and ultimately for a complete eradication. The current work intends to present the main advantages and disadvantages of United States Food and Drug Administration (FDA) approved anti-HIV-1 drugs as well as plausible strategies for the design and development of more anti-HIV-1 compounds with better potency, favorable pharmacokinetic profiles, and improved safety issues.

show abstract

“…To our knowledge, this is the first review within the past ten years that provides a biopsychosocial characterization and interventions for comorbid psychostimulant use disorders and HIV. It is crucial to review the literature in the context of current HIV and SUD treatments, as there are ongoing investigations and implementation of novel interventions [31,32]. This review may guide researchers, clinicians, and health policy makers in investigating and mitigating the complex effects of HIV+/CUD+ and HIV+/MUD+ through more holistic and culturally informed approaches.…”

Section: Introductionmentioning

confidence: 99%

Neurological, Behavioral, and Pathophysiological Characterization of the Co-Occurrence of Substance Use and HIV: A Narrative Review

Vines,

Sotelo,

Giddens

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Combined antiretroviral therapy (cART) has greatly reduced the severity of HIV-associated neurocognitive disorders in people living with HIV (PLWH); however, PLWH are more likely than the general population to use drugs and suffer from substance use disorders (SUDs) and to exhibit risky behaviors that promote HIV transmission and other infections. Dopamine-boosting psychostimulants such as cocaine and methamphetamine are some of the most widely used substances among PLWH. Chronic use of these substances disrupts brain function, structure, and cognition. PLWH with SUD have poor health outcomes driven by complex interactions between biological, neurocognitive, and social factors. Here we review the effects of comorbid HIV and psychostimulant use disorders by discussing the distinct and common effects of HIV and chronic cocaine and methamphetamine use on behavioral and neurological impairments using evidence from rodent models of HIV-associated neurocognitive impairments (Tat or gp120 protein expression) and clinical studies. We also provide a biopsychosocial perspective by discussing behavioral impairment in differentially impacted social groups and proposing interventions at both patient and population levels.

show abstract

Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?

Cited by 6 publications

References 34 publications

A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

A Review on FDA Approved Anti-HIV-1 Drugs, Anti-Gag Compounds and Potential Strategies for HIV-1 Eradication

Neurological, Behavioral, and Pathophysiological Characterization of the Co-Occurrence of Substance Use and HIV: A Narrative Review

Contact Info

Product

Resources

About